Dimensional and Developmental Approach to Psychotic Episodes in Children and Adolescents: Impact on Clinical Management
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 6
- 主要终点
- Lifetime Dimensions of Psychosis Scale-Child and Adolescent Version
研究概览
简要总结
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings, comprehensive cognitive assessments, neuroimaging and DNA (copy number variant) analyses (in families and patients who agree), and follow-up of course of illness, cognitive status and treatment response to specific antipsychotic drugs. The goal of the study is to test a prior hypothesis about clinical subgroups in this population and to test whether these subgroups predict antipsychotic medication response.
详细描述
This study relates to the organization of a collection of clinical, biological / genetic and radiological (MRI) data from people with a psychotic episode and from their families. These data will be analyzed to clarify whether there is a different response to antipsychotic treatment based on developmental and clinical expression.To answer the question asked in the research, it is planned to include people with at least one psychotic episode,The target population will be a prospective cohort of patients admitted to a hospital or psychiatric clinic for the treatment of psychotic symptoms.Comprehensive medical evaluation will be carried out according to the clinical features and medical history of each patient, to identify medical causes of psychosis. Comprehensive neuropsychological and speech / language evaluation will be completed. A child psychiatrist-diagnostician will complete the Lifetime Dimensions of Psychosis Scale - Child and Adolescent version at baseline. When the patient and parents agree, structural and functional MRI examinations will also be completed, and blood will be drawn for DNA extraction and analysis. Selected assessments (including evaluation of treatment response to specific antipsychotic drugs) will be performed at follow-up visits after 1, 3 and 5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 7 Years 至 20 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •for the Patient:
- •Children and young adults ages 7-20 years with age of onset of psychotic disorder between 7-17 years.
- •Hospitalized or seen for out-patient treatment for a psychotic episode, acute or chronic.
- •DSM-V diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or major depressive episode with psychotic features.
- •Written informed consent signed by the parents or the individual(s) with legal parental authority, and by the minor patient if his/her condition permits.
- •Written informed consent signed by the patient if he/she is a major, after clinical stabilization (not delusional).
- •Has health insurance coverage from Social Security (France) (not AME coverage).
- •Inclusion Criteria for parents or siblings wishing to participate in the genetic part of the study :
- •Parents : no specific criteria.
- •Siblings : siblings are eligible to participate if there are at least two first-degree relatives with psychotic disorders (including the patient) in the family.
- •Written informed consent for the genetic part of the study signed by any participating parents and siblings.
- •Has health insurance coverage from Social Security (France) (not AME coverage).
排除标准
- •Moderate or severe intellectual deficiency (IQ < 50).
- •Psychoses judged to be secondary to medical illness, medication effects or drugs of abuse.
- •Diagnosis of bipolar disorder.
- •Patients who are under legal guardianship.
- •For the neuroimaging part of the study only : any contraindications to Magnetic Resonance Imaging.
研究组 & 干预措施
prospective cohort
prospective monitoring of children and adolescents with schizophrenia and related psychotic disorders
干预措施: clinical, neuroimaging and DNA assessments (Other)
结局指标
主要结局
Lifetime Dimensions of Psychosis Scale-Child and Adolescent Version
时间窗: 4 months
Symptoms are rated for lifetime duration and for severity during the worst two-week period. Number of participants assigned to each of four clinical clusters derived by cluster analysis from clinical and developmental ratings on this scale as previously described.
次要结局
- Clinical global impressions scale - change version(at 5 years)
- Cortical gray matter volume (Magnetic Resonance Imaging)(up to 4 months)
- Stability of clinical profile on Lifetime Dimensions of Psychosis Scale-Child and Adolescent Version(at 5 years)